Testing Rademikibart for asthma or COPD flare-ups
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests an investigational drug called Rademikibart for people having a severe asthma or COPD flare-up that needs emergency care and steroids. The study aims to see if the drug can help control the flare-up faster and reduce the need for more treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a doctor's diagnosis of asthma or COPD and are currently having a flare-up that needs urgent care.
- You are receiving steroids (like prednisone) for this flare-up.
- During this flare-up, your blood test shows a certain type of white blood cell (eosinophil count) at 300 or higher.
- You weigh at least 40 kg (88 lbs) if you have asthma, or 45 kg (99 lbs) if you have COPD, and your BMI is 45 or less.
- You have had at least one flare-up in the past that needed steroid treatment.
- You are not pregnant or breastfeeding, and you do not have certain other health conditions like unstable heart disease or a recent cancer.
- You have not received certain other experimental or immune-modulating drugs recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine, felcorekibart, to see if it can reduce COPD flare-ups better than a placebo after 52 weeks. It's designed for people with high eosinophils, a type of white blood cell linked to inflammation.
This study tests a new medication (GSK5784283) for people with moderate to severe COPD who have a certain type of inflammation (eosinophilic). Participants must be on standard inhaler therapy and have a history of smoking. The trial will compare the new drug to a placebo.
This trial tests an injection called RC1416 for people with moderate-to-severe COPD who still have flare-ups despite using triple inhaler therapy. It may help reduce those flare-ups and improve breathing.
This study aims to improve care for people with asthma who are at higher risk of severe flare-ups. It may test new ways to manage asthma and help you avoid hospital visits.
This trial tests a new medicine called lunsekimig for people with COPD that still causes flare-ups despite standard treatment. It focuses on people with higher blood eosinophils (a type of white blood cell). If you smoke or used to smoke and have had at least 2 moderate or 1 severe flare-up in the past year, this study may be an option.
This study tests a new medicine called Lunsekimig for people with COPD that has frequent flare-ups and high eosinophil levels (a sign of inflammation). It aims to see if it can help control symptoms better than a placebo (a dummy treatment).
Hear when a new Asthma Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.